Iohexol
- Iohexol
- Iopaque®
- Solution and Powder for Injection
- 300mgI/mL
- Vial
- 50mL
Each 1mL Contains:
Iohexol 647mg
Equivalent to 300mg Iodine
Iohexol 647mg
Equivalent to 300mg Iodine
• Myelography
• Ventriculography
• Aortic Root and Arch Study
• Angiography
• CT Scanning of the Body
• Digital Subtraction
• Excretory Urography
• Hysterosalpingography
• Ventriculography
• Aortic Root and Arch Study
• Angiography
• CT Scanning of the Body
• Digital Subtraction
• Excretory Urography
• Hysterosalpingography
Mechanism of Action
Allows for radiographic visualization through the opacification of vessels and anatomical structures in the path of flow of the contrast media
Pharmacokinetics
Excretion: Urine (80-90%)
Contraindications
• Significant bacterial infection
• For procedural contraindications see package insert
Adverse Reactions
Headache, Mild to moderate pain including backache, neckache and stiffness, Nausea, and vomiting, Neuralgia, Rash, Erythema, Pruritus, Urticaria, Skin discoloration, Stevens-Johnson syndrome, Toxic epidermal necrolysis (SJS/TEN), Acute generalized exanthematous pustulosis (AGEP), Drug reaction with eosinophilia and systemic symptoms (DRESS)
Major Drug Interactions
-
Warnings
• Caution in combined renal/hepatic disease, severe multiple myeloma, anuria, CHF, severe arterial/venous disease
Recommendations for Patient
-
Pregnancy Considerations
Post marketing data with use in pregnant women are insufficient to determine if there is drug-associated risk of adverse developmental outcomes, drug crosses placenta and reaches fetal tissues in small amounts
Breastfeeding Considerations
Limited information indicates that maternal doses of iohexol up to 45.3 grams (containing 21 grams of iodine) produce low levels in milk. In addition, because iohexol is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Allows for radiographic visualization through the opacification of vessels and anatomical structures in the path of flow of the contrast media
Pharmacokinetics
Excretion: Urine (80-90%)
Contraindications
• Significant bacterial infection
• For procedural contraindications see package insert
Adverse Reactions
Headache, Mild to moderate pain including backache, neckache and stiffness, Nausea, and vomiting, Neuralgia, Rash, Erythema, Pruritus, Urticaria, Skin discoloration, Stevens-Johnson syndrome, Toxic epidermal necrolysis (SJS/TEN), Acute generalized exanthematous pustulosis (AGEP), Drug reaction with eosinophilia and systemic symptoms (DRESS)
Major Drug Interactions
-
Warnings
• Caution in combined renal/hepatic disease, severe multiple myeloma, anuria, CHF, severe arterial/venous disease
Recommendations for Patient
-
Pregnancy Considerations
Post marketing data with use in pregnant women are insufficient to determine if there is drug-associated risk of adverse developmental outcomes, drug crosses placenta and reaches fetal tissues in small amounts
Breastfeeding Considerations
Limited information indicates that maternal doses of iohexol up to 45.3 grams (containing 21 grams of iodine) produce low levels in milk. In addition, because iohexol is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people